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Abstract
Background: Peroxisome proliferator-activated receptor a (PPARa) regulates lipid metabolism in the liver. It is
unclear, however, how this receptor changes in liver cancer tissue. On the other hand, mouse carcinogenicity
studies showed that PPARa is necessary for the development of liver cancer induced by peroxisome proliferators,
and the relationship between PPARa and the development of liver cancer have been the focus of considerable
attention. There have been no reports, however, demonstrating that PPARa is involved in the development of
human liver cancer.
Methods: The subjects were 10 patients who underwent hepatectomy for hepatocellular carcinoma. We assessed
the expression of PPARa mRNA in human hepatocellular carcinoma tissue and non-cancerous tissue, as well as the
expression of target genes of PPARa, carnitine palmitoyltransferase 1A and cyclin D1 mRNAs. We also evaluated
glyceraldehyde 3-phosphate dehydrogenase, a key enzyme in the glycolytic system.
Results: The amounts of PPARa, carnitine palmitoyltransferase 1A and glyceraldehyde 3-phosphate dehydrogenase
mRNA in cancerous sections were significantly increased compared to those in non-cancerous sections. The level
of cyclin D1 mRNA tends to be higher in cancerous than non-cancerous sections. Although there was a significant
correlation between the levels of PPARa mRNA and cyclin D1 mRNA in both sections, however the correlation was
higher in cancerous sections.
Conclusion: The present investigation indicated increased expression of PPARa mRNA and mRNAs for PPARa
target genes in human hepatocellular carcinoma. These results might be associated with its carcinogenesis and
characteristic features of energy production.
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Background
Peroxisome proliferator-activated receptors (PPARs) are
extremely diverse metabolic regulators of mainly glycer-
olipids [1,2]. They are nowadays thought to play a cen-
tral role in energy homeostasis in response to changes
in the environment [3]. In recent years there have also
been reports that PPARs have antiinflammatory proper-
ties [4,5] and contribute to the control of cell prolifera-
tion signals and apoptosis [6,7]), so that they have
become a focus of considerable attention with regard to
metabolic diseases such as diabetes and hyperlipidemia,
as well as severe diseases including inflammatory disor-
ders and cancer.
The energy metabolism of cancer cells is known to
have peculiar characteristics that differ from those of
normal cells, although the details remain sketchy.
Among PPARs, peroxisome proliferator-activated recep-
tor a (PPARa) is found mainly in the liver, where it is
known to regulate lipid metabolism [8]. It is unclear,
however, how PPARa and other factors are associated
with metabolic changes in liver cancer tissues, and the
question of the kinds of changes that occur in energy
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great interest.
From carcinogenesis experiments using mice it is well
known that PPARa is necessary for development of liver
cancer induced by peroxisome proliferators [9], and the
relationship between PPARa and the development of
liver cancer has been the focus of considerable attention.
There have been no reports, however, on findings in
human liver cancer.
In the present study we assessed the expression of
PPARa mRNA in human hepatocellular carcinoma
(HCC) tissues and non-cancerous tissues, as well as the
expression of target genes of PPARa, carnitine palmi-
toyltransferase 1A (CPT1A) and cyclin D1 mRNAs, to
clarify one part of the relationship between carcinogen-
esis and the energy metabolism characteristics of liver
cancer cells. We also evaluated glyceraldehyde 3-phos-
phate dehydrogenase (G3PDH), a key enzyme in the gly-
colytic system in both tissues.
Materials and methods
The subjects were 10 patients at our institution who
underwent hepatectomy for HCC. Samples from cancer-
ous and non-cancerous sections of the resected speci-
mens were quickly frozen and stored at -80°C until they
were used for measurement. Only samples for which the
diagnosis of HCC had been confirmed pathologically
were used. Background liver had chronic hepatitis or
cirrhosis, and the level of the cirrhosis was A or B in
Child’s classification.
The current study was reviewed and approved by the
ethical review board at Aichi Medical University.
Informed consent was obtained from each patient.
Reverse transcription and PCR amplification
Total RNA from a sample of about 90 mg was isolated
by a modified guanidinum isothiocyanate method [10]
with the ISOGEN reagent (Nippon Gene Co. Ltd.,
Tokyo, Japan). RNA concentrations were spectrophoto-
metrically determined. First-strand cDNA synthesis of 5
μg total RNA was performed using oligo(dT) primers
following instructions of the manufacturer; SuperScript
First-Strand Synthesis System for RT-PCR, (Invitrogen
Life Technologies, Carlsbad, California, USA). Reverse
transcription for 18S rRNA analysis was carried out
using random hexamers. Amplifications of the target
cDNAs were performed using the following synthetic
oligonucleotides obtained from Rikaken Co., Ltd.
(Nagoya, Japan).
PPARa: forward 5’-CCAGTATTTAGGAAGCTGTCC
-3’ and reverse 5’-AAGTTCTTCAAGTAGGCCTCG-3’;
CPT1A: forward 5’-AGACGGTGGAACAGAGGCT-
GAAG-3’ and reverse 5’-TGAGACCAAACAAAGT-
GATGATGTCAG-3’;
G3PDH: forward 5’-AACAGCGACACCCACTCCTC-
3’ and reverse 5’-CCAGGAAATGAGCTTGACAA;
Cyclin D1: forward 5’-CCGTCCATGCGGAAGATC-3’
and reverse 5’-ATGGCCAGCGGGAAGAC-3’;
18S rRNA: forward 5’-CGACGACCCATTCAAAAA
TC-3’ and reverse 5’-AACCCTGATTCCCCATCAC-3’.
The primer sets yield products of 432, 81, 492, 86, and
90 base pairs for CPT1A, G3PDH, PPARa, cyclin D1,
and 18S rRNA, respectively. PCR reactions (25 μlf i n a l
volume) were carried out in a TaKaRa PCR Thermal
Cycler model TP3000 (TaKaRa Biomedicals, Ohtsu,
Japan) using the following cycle conditions: denaturation
at 94°C for 30 sec, annealing for 50 sec, and extension
at 72°C for 50 sec. Annealing temperatures were 58, 54,
54, 60, and 56°C for CPT1A, G3PDH, PPARa, cyclin
D1, and 18S rRNA, respectively. The numbers of cycles
for amplification of CPT1A, G3PDH, PPARa, cyclin D1,
and 18S rRNA templates were 28, 23, 29, 35, and 35,
respectively, as confirmed to be within the linear range
of amplification in preliminary experiments. PCR pro-
ducts (10 μl reaction mixture) were run on 1.5% agarose
gels and visualized by ethidium bromide staining. Sig-
nals on the gels were visualized by UV transillumination,
the gels were photographed, and the images were ana-
lyzed by scanning densitometry using the Scion Image
Beta 4.02 software (Scion Corporation, Frederick, Mary-
land, USA).
mRNA levels for CPT1A, G3PDH, PPARa, and cyclin
D1 in each sample were normalized by the amount of
18S rRNA.
Statistical analysis
Results were expressed as means ± SEM. Comparison of
the difference between the mean values of two groups
w a sm a d eb yt h eM a n n - W h i t n e y ’s U test. Correlation
between expression levels of PPARa and cyclin D1
mRNAs was obtained with the Spearman’s rank correla-
tion test. A difference with a P value of < 0.05 was con-
sidered statistically significant.
Results
Gene expression analysis
Representative photographs of PCR products of 18s
rRNA, PPARa, CPT1A, G3PDH and Cyclin D1 mRNAs
in cancerous and non-cancerous sections were shown in
Figure 1.
Comparison of expression levels of PPARa,C P T 1 A ,
G3PDH and cyclin D1 mRNAs in cancerous and non-
cancerous sections
Figure 2 shows the levels of PPARa,C P T 1 A ,G 3 P D H
and cyclin D1 mRNA expression in cancerous and non-
cancerous sections. The values are expressed as a ratio
of the mRNA amount in cancerous sections to that in
non-cancerous sections. The amounts of PPARa and
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Page 2 of 6CPT1A mRNAs in cancerous sections were 277 ± 49%
and 237 ± 36%, respectively, compared to those in non-
cancerous sections. These were statistically significant
differences (P <0 . 0 1a n dP < 0.05, respectively). The
amount of G3PDH mRNA in cancerous sections was
167 ± 12%, compared to that in non-cancerous sections.
This was also statistically significantly different (P <
0.01). The level of cyclin D1 mRNA tended to be higher
in cancerous sections (154 ± 16%) than in non-cancer-
ous sections, although the difference did not reach a sta-
tistically significant level (P = 0.079). The levels of 18S
rRNA in non-cancerous and cancerous sections were
nearly the same, at 100.0 ± 5.0% and 97.3 ± 5.3%,
respectively.
Figure 3 shows the correlation between expression
levels of PPARa and cyclin D1 mRNAs in non-cancer-
ous sections and cancerous sections. A significant corre-
lation was seen in non-cancerous sections and
cancerous sections; the regression coefficient and P
value of non-cancerous sections were 0.80 and 0.004
and those of cancerous sections were 0.74 and 0.006,
respectively.
Level of 18S rRNA, the internal standard, in non-can-
cerous sections and cancerous sections
The levels of 18S rRNA in non-cancerous and cancer-
ous sections were nearly the same, at 100.0 ± 5.0% and
97.3 ± 5.3%, respectively.
Discussion
Cancer cells have a characteristic energy production sys-
tem which differs from that in normal cells. The 18-
Fluoro-2-deoxyglucose (FDG) positron emission tomo-
graphy (FDG-PET), which is recently employed in diag-
nosing the presence of cancer and treatment
monitoring, also takes advantage of these characteristics
in cancer cells [11]. In general, the glucose metabolism
PPARα  CPT1A 
G3PDH cyclin D1 
18s rRNA 
Figure 1 Representative photographs of each PCR product in cancerous and non-cancerous sections. Representative photographs of PCR
products of 18s rRNA, PPARa, CPT1A, G3PDH and Cyclin D1 mRNAs in cancerous and non-cancerous sections were shown.
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levels of glucose transporter proteins and increased
levels of intracellular enzymes that promote glycolysis,
such as hexokinase and phosphofructokinase. In most
malignant cells, the relatively low levels of glucose-6-
phosphate lead to accumulation and trapping of FDG
intracellularly, allowing the visualization of increased
FDG uptake compared with normal cells. However,
there are several types of cancer that have low visualiza-
tion rates of the focus with FDG-PET [12,13]. Compared
with other cancers, these cancers are presumed to have
different characteristics in their energy metabolism.
H C Ci si n c l u d e di nt h i sl o wv i s u a l i z a t i o nr a t eg r o u p
[14].
The liver is the main target organ of PPARa metabolic
action. Activation of PPARa in liver cells induces
expression of acyl-CoA synthase, CPT1A 8 (the rate-
limiting enzyme of fatty acid b-oxidation system) and
other proteins necessary for the transport of fatty acids
into the mitochondria, the site of the ß-oxidation system
[15,16]. The results of this study suggest that the expres-
sion of PPARa mRNA is upregulated in HCC tissues
compared with non-cancerous tissues. Results similar to
those for PPARa were also obtained for CPT-1A mRNA
expression.
It is generally said that sugar metabolism is highly
enhanced in cancer tissues. With the aim of assessing
the state of sugar metabolism in normal and cancerous
liver cells, we evaluated the abundance of mRNA of
G3PDH, a key enzyme in the glycolytic system. The
level of G3PDH mRNA was certainly increased in can-
cerous sections. However, we previously reported a
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Figure 2 Comparison of expression levels of PPARa, CPT1A, G3PDH and cyclin D1 mRNAs in cancerous and non-cancerous sections.
Values are expressed as the ratio of the mRNA amount in cancerous sections to that in non-cancerous sections. Amounts of PPARa, CPT1A and
G3PDH mRNAs in cancerous sections were significantly higher, compared to those in non-cancerous sections. The level of cyclin D1 mRNA
tended to be higher in cancerous sections than in non-cancerous sections, although the difference did not reach a statistically significant level.
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kinase (PDK) mRNA in HCC tissue and non-cancerous
tissue [17]. In this report, there tended to be less PDK
in HCC tissues than in non-cancerous tissues. PDK
inactivates the pyruvate dehydrogenase complex (PDC),
which is a key enzyme in systems that produce energy
by glucose oxidation [18]. Therefore, PDK plays an
important role in regulation of glucose oxidation. These
results suggest that glucose oxidation might play a less
i m p o r t a n tr o l ei ne n e r g yp r o d u c t i o ni nH C Ct i s s u e s
compared with other cancer tissues.
There is a possibility that lipids rather than carbohy-
drates might be mainly used in the energy production in
HCC tissue. Thus, one reason there is not a high visuali-
zation rate of HCC on FDG-PET may be that, in com-
parison with other types of cancer, there is less use of
carbohydrates in HCC cells.
PPARa has been a focus of recent attention in terms
of its relationship with carcinogenesis. Long-term
administration of peroxisome proliferators in mice leads
to the development of HCC [9], but in PPARa knock-
out mice this phenomenon is not seen [19]. PPARa may
be understood to function as an oncogene in this
model. In addition, continuous activation of PPARa
increases the expression of cell cycle regulatory factors
such as cyclin and cyclin-dependent kinase, and inhibits
apoptosis [7]. Tatsumi et al. [20] demonstrated
activation of RXRa, a heterodimer partner of PPARa,i n
HCV core protein transgenic mice, and speculated that
PPARa contributes to the development of human HCC.
The cyclin D1 encodes the regulatory subunit of a
holoenzyme that phosphorylates and inactivates the Rb
protein and promotes progression through G1 to S
phase of the cell cycle. Over expression of cyclin D1
plays important roles in the development of human can-
cers, including breast, melanoma and prostate [21-23].
In 1993, Zhang et al. [24] has indicated the amplification
and over expression of cyclin D1 in HCC. Reducing the
expression of cyclin D1 reportedly promotes the apopto-
sis of HCC in vitro [25,26]. We also indicated that the
level of cyclin D1 mRNA was increased in HCC tissues.
Moreover, a very strong correlation between PPARa
and cyclin D1 expression levels was seen in HCC tis-
sues. This indicates that in tissue with enhanced expres-
sion of PPARa, the expression of cyclin D1 will also be
enhanced. Activation of PPARa reportedly contributes
to the carcinogenesis process for liver cancer, and the
results of this study indicate the possibility that this may
also hold true for humans. However, as is often pointed
out, increases in peroxisome proliferation and incidence
of HCC have not been demonstrated in patients who
take peroxisome proliferators long term [27], so we can-
not say with certainty that PPARa contributes to the
development of liver cancer in humans.
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Figure 3 Correlation between expression levels of PPARa and cyclin D1 mRNAs in non-cancerous sections and cancerous sections.A
significant correlation was seen in non-cancerous sections and cancerous sections. The regression coefficient and P value of non-cancerous
sections were 0.80 and 0.004 and those of cancerous sections were 0.74 and 0.006, respectively.
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Page 5 of 6Conclusions
The present investigation indicated increased expression
of PPARa mRNA and mRNAs for PPARa target genes
in human hepatocellular carcinoma. These results might
be associated with its carcinogenesis and characteristic
features of energy production, but further study is
warranted.
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